{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibsauxthc52pgykqw3qpsk7xqvncpkfizoaifvt4ey5jlbkk3buam",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mlvayewmoni2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiajyzwqwbn4foqydui5u77akb4dela5sn3sxa5dclo6habrdal4uy"
    },
    "mimeType": "image/jpeg",
    "size": 516555
  },
  "path": "/news/2026-05-wegovy-migraine-drug-women-year.html",
  "publishedAt": "2026-05-15T07:00:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A nationwide study from Denmark presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey, shows that use of semaglutide (Wegovy) for weight management is associated with a 7% reduction in the use of triptan-class drugs for treatment of migraine one year after initiation.",
  "title": "Wegovy initiation may cut migraine drug use 8% in women after one year"
}